The operational India-UK trade agreement reduces tariffs but requires compliance across five regulatory gates for pharmaceuticals and medical tech.
The India-UK Comprehensive Economic and Trade Agreement, effective 15 July, shifts focus from tariff cuts to multi-layered market access for pharmaceuticals and medical technology. The deal phases tariffs on 198 of 226 pharma lines immediately, with full elimination over five or ten years, while medical tech faces mixed reductions.
Market access now hinges on five regulatory gates: rules of origin, destination approvals, manufacturing compliance, public procurement terms, and cross-border operational legality. Tariff preferences apply only if products meet origin criteria, such as chemical reactions or value content, not mere repackaging or testing.
The agreement does not consolidate these gates but adjusts their requirements, signaling a more complex but structured pathway for trade in regulated sectors.